Christian Brenneis

Christian Brenneis

Auto-generated profile, based on publicly available information

Christian Brenneis

Karl Landsteiner Institute for Interdisciplinary Rehabilitation Research, Muenster, Austria

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 June 2025 in Archives of Toxicology
Verified
Journal Article
Open access
PDF file
SSStephanie Simon
Stephanie Simon
JSJörg Schlingemann
Jörg Schlingemann
GJGeorge Johnson
George Johnson
CBChristian Brenneis
Christian Brenneis
BGBrunhilde Guessregen
Brunhilde Guessregen
JDJessica Dieckhoff
Jessica Dieckhoff
N-nitroso-bisoprolol (NBP) is a nitrosamine drug substance-related impurity (NDSRI) of bisoprolol, which is used to treat cardiac diseases since decades. To investigate the mutagenic potential of NBP, in vitro methods such as Enhanced Ames Test (EAT) and a mammalian cell gene mutation (HPRT) assay were used. To assess the in vivo mutagenicity, a 28-day repeat-dose study was conducted in wild-type NMRI mice, and liver and bone marrow samples were subjected to error-corrected next-generation sequencing (i.e., duplex sequencing) followed by benchmark dose analysis (BMD). NBP did not show mutagenic effects in Ames tests using 10 % and 30 % induced rat or 30 % uninduced hamster S9. However, relevant increases in mutation frequencies were observed in an EAT in the presence of 30 % induced hamster S9 in strains TA100 and TA1535, confirming that the most stringent conditions of the EAT are appropriate to detect the mutagenic activity of weak mutagens, such as NBP. In the HPRT assay conducted in V79 cells, nitroso-diethylamine (NDEA) relevantly induced the mutation frequency, but not NBP. The highly sensitive error-corrected Next-Generation Sequencing (ecNGS) method to detect mutations across the genome represents an appropriate in vivo mutagenicity investigation equally suitable as a TGR assay to assess the mutagenic potential of nitrosamines. A weak induction of mutation frequencies was detected by ecNGS in the liver and the bone marrow of mice. Using BMD analysis, new safe limits were calculated for NBP, which are higher than the published AI of 1.5 µg/person/day. Using the approach to calculate Permissible Daily Exposure (PDE) limits according to ICH Q3C, a lifetime PDE of 400 µg/person/day was derived. Based on the ICH M7 framework for derivation of Acceptable Intake (AI) limits, an AI of 64 µg/person/day was established. Consistent with regulatory emphasis on mechanistic interpretation, in vivo modeling was further supported by in silico calculations. Specifically, the validated Computer-Aided Discovery and RE-design (CADRE) tool was used to predict the potency of NBP and further differentiate its metabolic activity from the anchor nitrosamine NDEA via quantum mechanics (QM) calculations and CYP-binding predictions. Outcomes of this analysis were consistent with in vivo studies, while offering a deeper understanding of the fundamental biochemistry using a physics-led method. The integrated in vivo–in silico investigation provides a data-based determination of safe limits, suggesting that the AI based on structural considerations solely might be over-conservative and should not be capped at the TTC.

14 February 2025 in JMIR Serious Games
Verified
Journal Article
Open access
SHSilvia Herren
Silvia Herren
BSBarbara Seebacher
Barbara Seebacher
SMSarah Mildner
Sarah Mildner
YRYanick Riederer
Yanick Riederer
UPUlrike Pachmann
Ulrike Pachmann
AMAnna Lisa Martin-Niedecken
Anna Lisa Martin-Niedecken
Background: Exergames are increasingly used in rehabilitation, yet their usability and user experience for patients and therapists, particularly for functional model systems, are underresearched. The diverse needs and preferences of users make conducting usability studies challenging, emphasizing the need for further investigation in real-world settings. Objective: This study aimed to evaluate the usability, safety, and user experience of a novel exergame functional model, the ExerG, from the perspectives of patients and therapists in a rehabilitation setting. Methods: In this mixed methods study, 15 patients undergoing rehabilitation (primary end users [PEUs]) and 20 therapists (secondary end users [SEUs]) from 2 rehabilitation centers in Switzerland and Austria participated in exercising and observation sessions with the ExerG. SEUs received training on system use and technical issue management, enabling them to fulfill their therapist roles while treating patients or mock patients. Rapid Iterative Testing and Evaluation was used and the training software adjusted based on participant feedback. Usability was assessed with questionnaires, semistructured interviews, and through observations during the ExerG testing. System acceptability was evaluated using specific quantitative thresholds based on PEU performance and feedback. An observation protocol tracked SEUs’ correct use, errors, hesitations, task completion time, and needed assistance across scenarios. Results: Patients and therapists reported overall good usability and positive experiences with the exergame. PEUs rated 23/29 (79%) instructions as acceptable, showed good-to-very-good exercise performance in 19/29 (65%) tasks, and completed 28/29 (97%) tasks. Patients reported no adverse events, showing improved performance and enjoyment across ExerG exercising rounds, with 79/90 (88%) expressing positive emotions and reporting median scores of 9 (IQR 7.5‐10) on a 1‐10 user satisfaction scale. Patients were willing to continue using the device if the graphic design was improved (5/15), tracking systems and projector quality were enhanced (each 3/15), instructions clarified (12/15), and the game variety increased (2/15). PEUs felt secure in the safety harness (15/15) but recommended swivel arm movement enhancements (5/15). SEUs effectively executed scenarios, with hesitation and difficulties observed in only 14/41 tasks and 2/41 tasks, across all 20 therapists, accounting for 1.7% and 0.2% of the 820 total task cases, respectively. Therapists’ quantitative usability ratings were high (median System Usability Scale score 82.5, IQR 65‐95). All SEUs expressed their willingness to use the ExerG (20/20) and reported being able to operate the system using the user handbook (20/20). They emphasized the motivation-enhancing effect of video-game based training (12/20) and considered the activities supportive for physical and cognitive skills (20/20). They suggested incorporating daily living task simulations (13/20), more customizable options (6/20), more targeted motivational feedback (9/20), clearer performance ratings (9/20), and more concise activity instructions (6/20). Conclusions: The interdisciplinary, iterative ExerG development approach shows promise. The findings will inform future optimizations. Future work will assess long-term impact.

11 July 2024 in BMJ Open
Verified
Journal Article
Open access
PDF file
BSBarbara Seebacher
Barbara Seebacher
BHBirgit Helmlinger
Birgit Helmlinger
IHIsabella Hotz
Isabella Hotz
DPDaniela Pinter
Daniela Pinter
RERainer Ehling
Rainer Ehling
CBChristian Brenneis
Christian Brenneis
Objectives To explore the experiences and acceptability of music-cued motor imagery (MCMI), music-cued gait training (MCGT), and combined MCMI and MCGT (MCMI-MCGT) in people with multiple sclerosis (pwMS). We also aimed to explore participants’ self-rated health status postintervention and gather recommendations for further programme development. Design Qualitative study alongside the double-blind randomised controlled real and imagined gait training with music-cueing (RIGMUC) multicentre trial of MCMI, MCGT and MCMI-MCGT. Setting PwMS recruited for the RIGMUC trial from Departments of Neurology at Medical Universities of Innsbruck and Graz and Clinic for Rehabilitation Muenster, Austria. Participants All 132 pwMS with mild to moderate disability randomised into the trial were included in the analysis. Methods Participants practised home-based MCMI, MCGT or MCMI-MCGT for 30 min, 4×/week, for 4 weeks. Three trained researchers conducted weekly semistructured telephone interviews during the intervention period, supporting adherence, addressing problems, sharing experiences and assessing intervention acceptability. Follow-up interviews at 4-week postintervention aimed to understand participants’ self-rated changes in walking, fatigue and overall health compared with their prestudy condition. Investigator triangulation was employed among the researchers to enhance trustworthiness and credibility. Results Using thematic analysis, we identified five themes: (1) empowerment, (2) remaining in sync, (3) interconnection between imagined and actual walking, (4) sustaining focus and (5) real-world transfer. Participants appreciated and found the imagined and actual MCGT innovative. Problems included concentration issues, early fatigue in advanced disability and difficulty synchronising with music cues. Positive changes in walking, fatigue and overall health postinterventions were reported offering valuable insights for programme development. Conclusions A participatory study to codevelop a music-cued exercise programme for pwMS seems appropriate as participants appreciated the innovation and effectiveness of both imagined and actual MCGT. Future studies should also investigate pwMS’ potential and limitations in enhancing their MCMI abilities with intensive therapist-supported practice. Trial registration number DRKS00023978.

24 November 2024 in BMJ Open
Verified
Journal Article
Open access
PDF file
BFBernhard Fasching
Bernhard Fasching
SMSarah Mildner
Sarah Mildner
FFFranziska Fink
Franziska Fink
AWAndreas Wanitschek
Andreas Wanitschek
IHIsabella Hotz
Isabella Hotz
BSBarbara Seebacher
Barbara Seebacher
Objectives To collaboratively develop a music-supported video-based exercise programme for people with multiple sclerosis (pwMS) with mild to severe disability. Design and setting We performed this participatory mixed methods study from 15 March 2022 to 22 July 2023 at two Austrian multiple sclerosis (MS) centres. Participants This research included 67 pwMS, of whom 18 pwMS (including two patient representatives and five MS support group leaders/members) and an additional three family members served as stakeholders. Six neurologists and six physiotherapists, each with >5 years of experience in treating pwMS were interviewed. Intervention Stakeholders actively participated as members of study advisory, project steering and research groups. Researcher-supported peer-to-peer focus groups and individual interviews, conducted in three stages, gathered information on musical preferences and exercise needs. We co-developed, co-evaluated and co-adapted the music-supported exercise programme with the stakeholders. Involvement levels were measured using the Participation Check and Patient Public Involvement (PPI) Assessment Survey, self-efficacy with the Unidimensional Self-Efficacy Scale for Multiple Sclerosis and emotional states with the Self-Assessment Manikin. Results We identified four themes through reflexive thematic analysis: (1) engagement; (2) ease; (3) autonomy; (4) musical meaning. Integration of qualitative and quantitative components highlighted the success of PPI activities: (a) 148 co-created, free videos are publicly available; (b) four videos provide expert interviews with general information, while 144 offer music-supported exercises tailored to pwMS with mild to severe disability; (c) patients found the videos relevant, feasible and usable in interviews and focus groups; (d) ‘easy’ category exercises (seated or lying) are suitable for severely affected pwMS; (e) stakeholders felt included, respected and heard, as shown by quantitative PPI assessments. Conclusions Stakeholders were essential in identifying key aspects, preferences and constraints early on. Their feedback on music and exercise shaped the project. This study transformed our approach to exercise for pwMS. Future studies are required to evaluate the programme’s efficacy. Trial registration number DRKS00027979.

4 April 2025 in JMIR Serious Games
Verified
Journal Article
Open access
SHSilvia Herren
Silvia Herren
BSBarbara Seebacher
Barbara Seebacher
SMSarah Mildner
Sarah Mildner
YRYanick Riederer
Yanick Riederer
UPUlrike Pachmann
Ulrike Pachmann
AMAnna Lisa Martin-Niedecken
Anna Lisa Martin-Niedecken

7 October 2026 in Science Translational Medicine
Verified
Journal Article
Closed access
SKShashank Kulkarni
Shashank Kulkarni
SPSang-Kyu Park
Sang-Kyu Park
YHYoussef Hamway
Youssef Hamway
LFLukas Friedrich
Lukas Friedrich
JKJesko Kaiser
Jesko Kaiser
TSThomas Spangenberg
Thomas Spangenberg
Schistosomiasis, a neglected tropical disease caused by infection with parasitic blood flukes of the genus Schistosoma , affects more than 250 million people worldwide. Currently, patients rely on a single medicine, praziquantel (PZQ), discovered half a century ago. To combat drug resistance and reach elimination of the schistosome parasite, alternative drugs to PZQ are required that treat and prevent disease. Here, we describe a drug candidate, M5493, with potent activity against multiple parasite life cycle stages. The target is a parasite transient receptor potential ion channel, distinct from the target of PZQ. To circumvent its limited bioavailability, the active agent was converted to prodrug M5493, which displayed robust activity against the schistosome parasite at doses as low as 5 milligrams per kilogram in mice infected with Schistosoma mansoni . Unlike the benzodiazepine meclonazepam, which displays clinical antihelminthic activity through the same target, M5493 showed no sedating side effects given that it did not engage GABA A receptors. Overall, this compound has the potential to provide single-dose treatment, broad-spectrum efficacy against schistosome parasites at different life cycle stages, and transmission blocking activity.